| Multiple Sclerosis, Secondary Progressive
Betaseron vs Mavenclad
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, secondary progressive.Deep comparison between: Betaseron vs Mavenclad with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMavenclad has a higher rate of injection site reactions vs Betaseron based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mavenclad but not Betaseron, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Betaseron
Mavenclad
At A Glance
SC injection
Every other day
Type I interferon
Oral
2 yearly treatment courses
Nucleoside metabolic inhibitor
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Clinically isolated syndrome
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Multiple Sclerosis, Relapsing-Remitting, Clinically isolated syndrome, Multiple Sclerosis, Secondary Progressive Start at 0.0625 mg (0.25 mL) SC every other day, titrating over six weeks to the recommended dose of 0.25 mg (1 mL) SC every other day.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Cumulative dose of 3.5 mg/kg administered orally, divided into 2 yearly treatment courses (1.75 mg/kg per course); each course consists of 2 cycles of 4 to 5 consecutive days of dosing; no more than 2 tablets (20 mg) per day; do not administer additional treatment during the 2 years following completion of 2 courses.
Contraindications
- History of hypersensitivity to natural or recombinant interferon beta, Albumin (Human), or any other component of the formulation
- Current malignancy
- Pregnancy, or women or men of reproductive potential not using effective contraception during dosing and for 6 months after the last dose in each treatment course
- HIV infection
- Active chronic infections (e.g., hepatitis or tuberculosis)
- History of hypersensitivity to cladribine
- Breastfeeding on a treatment day and for 10 days after the last dose
Adverse Reactions
Most common (>=5% difference from placebo) Injection site reaction, lymphopenia, flu-like symptoms, myalgia, leukopenia, neutropenia, increased liver enzymes, headache, hypertonia, pain, rash, insomnia, abdominal pain, asthenia
Serious Hepatic injury, anaphylaxis and allergic reactions, depression and suicide, congestive heart failure, injection site necrosis, leukopenia, thrombotic microangiopathy, pulmonary arterial hypertension, seizures, drug-induced lupus erythematosus
Postmarketing Anemia, thrombocytopenia, hemolytic anemia, hypothyroidism, hyperthyroidism, pancreatitis, bronchospasm, pulmonary arterial hypertension, fatal capillary leak syndrome
Most common (>20%) Upper respiratory tract infection, headache, lymphopenia
Serious Malignancies, teratogenicity, lymphopenia, infections, hematologic toxicity, graft-versus-host disease with blood transfusion, liver injury, hypersensitivity, cardiac failure, seizures, myelodysplastic syndrome
Postmarketing Nocardiosis, varicella zoster, histoplasmosis, cryptococcosis, toxoplasmosis, liver injury
Pharmacology
Interferon beta-1b is a type I interferon that binds to specific receptors on human cell membranes, inducing immunomodulatory effects including enhancement of suppressor T cell activity, reduction of pro-inflammatory cytokine production, down-regulation of antigen presentation, and inhibition of lymphocyte trafficking into the central nervous system; its specific mechanism of action in multiple sclerosis is unknown.
Cladribine is a nucleoside metabolic inhibitor that exerts cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes; this lymphocyte-depleting mechanism is thought to underlie its therapeutic effects in relapsing forms of multiple sclerosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Betaseron
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Mavenclad
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Betaseron
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (4/8)
Mavenclad
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Betaseron
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Mavenclad
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BetaseronView full Betaseron profile
MavencladView full Mavenclad profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.